by paul | Dec 5, 2023 | Blog, Uncategorized
Following a period of open comment, public advisory committee meetings, and closed-door deliberations, FDA is mandating changes to iPLEDGE, the Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin for acne. The Isotretinoin Product Manufacturers Group...
by paul | Dec 5, 2023 | Blog, Uncategorized
The Phase III clinical trial is now underway to evaluate fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) from Ascletis Pharma, Inc. for treatment of moderate to severe acne vulgaris.The randomized, double-blind, placebo-controlled, multicenter clinical trial...
by paul | Nov 1, 2023 | Blog
The FDA has approved Cosentyx® (secukinumab) from Novartis to treat moderate to severe hidradenitis suppurativa (HS) in adults. It is approved as a 300mg dose, administered every four weeks, with the option to increase to every two weeks if the patient has an...
by paul | Oct 31, 2023 | Blog, Uncategorized
Most teens in the UK will need sign-off from two healthcare professionals before they can receive isotretinoin for severe acne, according to new regulations enacted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Other safety measures introduced...
by paul | Oct 22, 2023 | Blog, Uncategorized
The first and only fixed-dose, triple-combination topical treatment for acne has received FDA approval. Cabtreo™ (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% from Ortho Dermatologics is indicated for the topical treatment of acne...
